CalciMedica Welcomes Stephen Bardin As New Chief Financial Officer

CalciMedica, Inc., a clinical-stage biopharma company developing innovative calcium release-activated calcium (CRAC) channel inhibitors for treating acute and chronic inflammatory and immune conditions, has appointed Stephen Bardin as its new Chief Financial Officer. This transition will coincide with the departure of Daniel Geffken, the current Interim CFO, following the filing of CalciMedica’s third-quarter financials.

"We are delighted to bring Stephen on board. He is a skilled and experienced biotechnology executive who will be invaluable to CalciMedica as we advance our clinical-stage pipeline. Stephen has been advising us on various strategic matters for several months and, most recently, was critical in executing our successful public financing last week.

We look forward to his many future contributions as he joins us full-time,” said in a statement, Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica. 

Stephen Bardin joins CalciMedica and has substantial experience in capital raising, corporate development, and strategic finance. He most recently served as CFO at atai Life Sciences, leading investor relations, business development, and capital allocation. Before atai, Bardin spent nearly three years at BridgeBio Pharma, Inc., overseeing various finance initiatives and securing over $2 billion through diverse funding efforts. 

His background includes finance, operations, and corporate development roles at Myovant Sciences, previously under Roivant. He began his career consulting for life sciences companies at the Boston Consulting Group. Bardin holds an M.B.A. from Stanford Graduate School of Business and graduated summa cum laude with a B.S.E. in Biomedical Engineering from Duke University.

Mr. Stephen Bardin stated, "CalciMedica has made impressive recent progress, delivering compelling clinical data for large and underserved patient populations. The CARPO Phase 2b data in patients with acute pancreatitis announced last month is promising and provides an optimistic readthrough to KOURAGE, CalciMedica's Phase 2 trial in acute kidney injury, which is expected to read out next year. I look forward to working more closely with the team as we advance AKI in the clinic and prepare for a Phase 3 program in AP."